Renal dosimetry: Ready for biological equivalent dose? response to medical internal radiation dose and european association of nuclear medicine committee letters

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 6, 2010, Pages 763-765

  Siegel, Jeffry A ^a   Stabin, Michael G ^b   Sharkey, Robert M ^c  

^a Nuclear Physics Enterprises   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR THERAPY AGENT; PEPTIDE RADIONUCLIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

DOSIMETRY; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; HUMAN; LETTER; MEDICAL SOCIETY; NEPHROTOXICITY; NUCLEAR MEDICINE; PEPTIDE RADIONUCLIDE RECEPTOR THERAPY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOISOTOPE THERAPY; RENAL DOSIMETRY; TREATMENT RESPONSE;

DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KIDNEY; MODELS, BIOLOGICAL; PAMPHLETS; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; RADIATION DOSAGE; RADIATION INJURIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, PEPTIDE;

EID: 78651321677     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0878     Document Type: Letter

References (13)

1. Siegel JA, Stabin MG, Sharkey RM. Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm 2010;25:581.
2. Siegel JA, Stabin MG, Sharkey RM. Renal dosimetry: Ready for Biological Effective Dose? Cancer Biother Radiopharm 2010;25:589.
3. 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46(suppl):99S.
4. 177Lu-DOTATATE: The role of as-sociated risk factors. Eur J Nucl Med Mol Imag 2008;35:1847.
5. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD Pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response\implications for radionuclide therapy. J Nucl Med 2008;49:1884.
6. Wessels BW, Sgouros G. Renal Dosimetry.Cancer Biother Radiopharm 2010;25:597.
7. Lassmann M, Strigari L, Bardies M. Dosimetry is alive and well. Cancer Biother Radiopharm 2010;25:593.
8. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodis-tribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S.
9. Buijs WCAM, Siegel JA, Boerman OC, Corstens FHM. Ab-solute organ activity estimated by five different methods of background correction. J Nucl Med 1998;39:2167.
10. 90Y-DOTATOC therapies in patients with neuroendocrine tu-mors. Cancer Biother Radiopharm 2007;22:130.
11. Voit EO, Yi PN. Comparison of isoeffect relationships in radiotherapy. Bull Math Biol 1990;52:657.
12. Howell RW, Goddu SM, Rao DV. Application of the linear-quadratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides. J Nucl Med 1994;35:1861.
13. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 2004;19:378.